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Background/Aim: Severe bone pain is experienced by 60–80% of patients with metastatic bone disease,
and has a profound impact on quality of life. Therefore, effective pain relief is an important goal in
managing metastatic bone disease. Orthopedic surgeons are often challenged with patients presenting
with newly diagnosed bone metastases and severe and disabling bone pain. It is important to provide
fast and sufﬁcient analgesia. Clinical trials have demonstrated that bisphosphonates reduce effectively
and sustained bone pain by approved standard dosage over time. Open label prospective trials have
shown that short time high dose i.v. Ibandronate is effective in rapid pain relief in different primary
tumors.
Patients and methods: In 33 patients with metastatic bone pain from newly diagnosed skeletal metas-
tases we utilized the loading-dose concept for intravenous ibandronate (6 mg infused over 1 h on
3 consecutive days).
Results: In 33 patients loading-dose ibandronate therapy signiﬁcantly reduced bone pain within the ﬁrst
5–7 days (VAS day 0: 6–8 vs. day 7: 3–4). Only 3 patients showed no response concerning a distinct pain
reduction within the ﬁrst days of therapy. There was no increase in pain medication.
Conclusion: This clinical observational study in selected patients with severe metastatic bone pain un-
dergoing an intensive high dosed ibandronate-therapy for a short period demonstrated that loading-dose
ibandronate (6 mg i.v., 3 consecutive days) resulted in a reduction of pain within days.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tumor metastases of the skeleton occur in up to 80% of patients
in progressed stages of cancer, most commonly in cases of breast,
lung, prostate, kydney and thyroid tumors [1,2]. Bone metastases
are often associated with pathologic fractures, hypercalcemia and
spinal cord compression, as well as severe bone pain [3]. Ortho-
pedic surgeons are challenged with patients presenting with
newly diagnosed bone metastases and severe and disabling pain.
Skeletal pain is commonly divided in 3 groups: ongoing pain, in-
cident breakthrough pain and movement-evoked breakthrough
pain [4,5]. Initially bone cancer patients most frequently suffer
from ongoing pain, hurting as a dull, constant throbbing pain that
intensiﬁes with time [6]. In advanced stages of bone cancer ex-
treme pain can occur spontaneously, or after weight-bearing or
movement of the affected extremity [7]. Breakthrough pain isGmbH. This is an open access art
istocles Gluck Hospital, Hos-
ogy, Rosenstr. 2, d-40882 Ra-difﬁcult to control, often high doses of opioids and non-steroidal
drugs are required, accompanied by adverse effects like somno-
lence, cognitive impairment and constipation [4,6]. Metastatic
bone disease is a consequence of a tumorinduced imbalance of the
activities of osteoclasts and osteoblasts. Bisphosphonates have
been shown to be a real alternative by reducing bone pain from
metastases, probably by inhibiting the underlying processes of
osteoclast-mediated bone resorption [1]. First- and second-gen-
eration bisphosphonates like clodronate or pamidronate, showed
signiﬁcant analgesic effects in patients with metastatic bone pain
[8,9]. In the need for rapid relief of severe metastatic bone pain,
especially for breakthrough and opioid-resistent pain, without the
negative side effects of opioids, the third generation bispho-
sphonate Ibandronate has been examined as a possible treatment
option for patients suffering from metastatic breast cancer [2,10–
12]. A large multicenter study of patients with metastatic breast
cancer evaluated the impact of intravenous Ibandronate on ske-
letal-related events and bone pain. Patients treated with 6 mg
Ibandronate intravenously every 4 weeks for 2 years experienced
signiﬁcant reduction in bone pain compared to a control group
[13]. Mancini et al. showed in 18 patients with metastatic boneicle under the CC BY-NC-ND license
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intravenously for 4 consecutive days signiﬁcantly reduced bone
pain scores within 7 days [2]. Patients attending orthopedic de-
partments with newly diagnosed bone metastatic disease are in
need of rapid pain relief before being transferred to further
treatment modalities. Therefore, the purpose of this current study
was to evaluate the short-term efﬁcacy and safety of loading dose
Ibandronate (6 mg intravenously administered for 3 consecutive
days by a 1 h infusion) in patients with newly diagnosed meta-
static bone disease of different primary tumors, suffering from
severe bone pain.2. Patients and methods
Thirty-three patients with symptomatic skeletal metastases
from different tumor origins were treated with intravenous Iban-
dronate in an open, prospective, non-randomized study. The
median age of patients was 59 years (33–78 yrs) (Table 1). All
patients had radiologically conﬁrmed bone metastases and were
experiencing opioid resistant pain in site of the skeletal metas-
tases. 23 patients described vertebral bone pain due to vertebral
metastases, 3 patients complained about hip pain, 7 patients de-
scribed all body pain. All of the patients were admitted due to the
bone pain, for none of the patients an orthopedic operation was
scheduled. None of the patients had received bone radiotherapy or
bisphosphonate therapy previously. Furthermore, patients were
excluded if they had moderate or severe hypercalcaemia (serum
calcium 412 mg/dL), impaired renal function (serum creatinine
41.5 mg/dL), a change to their hormonal treatment or che-
motherapy during 2 months before study entry.
During the study the patients received only Ibandronate plusTable 1
Patient characteristics.
Primary tumor Age in
yrs
Mean baseline VAS
pain score
Mean VAS pain
score at day 5–7
Breast 78 7 4
Breast 52 6 2
Breast 72 7 4
Breast 51 6 2
Breast 71 7 2
Breast 34 6 3
Breast 71 7 4
Breast 42 9 3
Breast 47 7 3
Breast 71 6 4
Breast 69 5 3
Breast 75 8 4
Breast 44 6 3
Breast 57 7 4
Breast 68 6 3
Breast 76 8 5
Breast 50 8 3
Breast 61 6 2
Breast 42 8 3
Breast 66 7 4
Renal Cell Carcinoma 69 7 5
Renal Cell Carcinoma 61 6 4
Renal Cell Carcinoma 51 7 3
Renal Cell Carcinoma 56 7 3
Renal Cell Carcinoma 62 8 5
Urothelium Carcinoma 74 7 7
Urothelium Carcinoma 69 7 3
Urothelium Carcinoma 64 8 5
Bronchial Carcinoma 63 8 7
Bronchial Carcinoma 52 8 2
Malignant Melanoma 57 7 3
Malignant Melanoma 67 6 3
Neuroendocrine tumor 33 7 3opioids and non-steroidal antiphlogistic drugs. Patients were
withdrawn from the study if they received other interventions
that could have affected their level of pain. Ibandronate 6 mg was
infused intravenously for 1 h on days 1, 2, 3 of the study. All pa-
tients were followed up until day 7 of the study. Physical ex-
aminations and assessments of vital signs were conducted on day
1 and every 2nd day thereafter. Efﬁcacy variables included pain,
and the use of analgesic. Bone pain was assessed using a visual
analog scale from 0 (no pain) to 10 (worst pain imaginable) [14].
Changes in pain severity during treatment were rated as im-
provement when the sum of decreases in pain scored between
visits outweighed the sum of increases [10]. Indirect measurement
of pain was received by using the Morphine Equivalent Daily Dose
(MEDD) index of opioid consumption. The MEDD is calculated as
the daily morphine dose (in milligrams) multiplied by an MEDD
factor of three for intravenous treatment, two for subcutaneous
therapy or one for oral treatment [14]. Adverse events were
monitored throughout the study (total of 7 days) and for 4 weeks
after. Laboratory parameters reﬂecting renal function and serum
calcium levels (Normal values, 8.5 to 10.3 mg/dl) were evaluated
every day throughout study time.
Data for each assessment point are expressed as the mean va-
lue plus standard deviation. One tailed paired t-tests were per-
formed to analyze the effects of ibandronate treatment. Sig-
niﬁcance level was set at po0.05.
The trial had been approved by the institutional ethics
committee.3. Results
The study included 33 patients with a variety of different pri-
mary tumors (Table 1). The median age of patients was 59 years
(33–78 yrs). The median duration of inpatient hospitalization be-
fore starting therapy was 1 day (0–2 days). All patients remained
hospitalized until they were transferred to further treatment
modalities (e.g. surgery, chemotherapy, radiation) with a median
stay of 9 days (range 7–10 days). At day 0, all patients enrolled in
the study were experiencing severe bone pain (mean visual analog
pain score 6.8 (6–8)) while receiving an equivalent of 400 mg/d
oral morphine. Pain intensity signiﬁcantly decreased on day 3–5
(mean VAS 4.9 (3–7)) (po0.01) and day 5–7 (mean VAS 3.7 (2–7))
(po0.01) compared to day 0 (mean VAS 6.8 (6–8)) (Fig. 1). Sig-
niﬁcant reductions from baseline in visual analog pain scores
while receiving ibandronate were not based on an increased use of
other analgetics. None of the patients showed an increase in
MEDD index throughout the study period (Fig. 2). Only one patient
not responding to Ibandronate needed additional analgesic mea-
sures with regularly used fentanyl patches. Side effects consisted
mainly of fever on the day following the ﬁrst intravenousFig. 1. : Mean VAS pain scores.
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ﬂu-like syndrome (fever, myalgia) that lasted for 48 h. No therapy
was discontinued due to adverse side effects. Renal function and
serum calcium levels (medium serum Calcium of 9.2 mg/dl at day
0 (range: 8.3 to 10.1), medium serum Calcium of 8.8 mg/dl at day 7
(range 8.1–9.9)) were in the physiological range in every
measurement.4. Discussion
In the current study, we were able to show that the adminis-
tration of loading-dose Ibandronate therapy (60 mg Ibandronate
infused intravenously over 1 h for 3 consecutive days) resulted in a
highly signiﬁcant decrease in pain levels in patients suffering from
metastatic bone disease. Pain reduction was rapidly seen, within
3–5 days after the ﬁrst infusion and accompanied by a substantial
reduction in analgesic use.
As with any open-label study, it is possible that a placebo effect
may have contributed to patients analgesia after initiation of the
therapy. A randomized placebo-controlled trial would be required to
ﬁnally prove the high analgesic effect of the loading-dose treatment
with Ibandronate in metastatic bone disease. However, our results
are consistent with previous reports. Two randomized, double-blind,
placebo-controlled multicenter studies examined the efﬁciency of
oral Ibandronate in bone pain relief. These studies were conducted
with near-identical protocols, allowing data to be pooled [15–17]. 564
patients with metastatic bone disease due to breast cancer were
randomised to receive oral Ibandronate 50 mg (n¼287) or placebo
(n¼277) once daily. In contrast to placebo, Ibandronate rapidly re-
duced bone-pain scores. With placebo, bone-pain scores did not
change for 36 weeks and then steadily increased over the next 60
weeks. After 60 weeks the difference in bone-pain score was sig-
niﬁcant comparing both groups (p¼0.001). Mean analgesic use in-
creased in both groups, but this increase was signiﬁcantly less in the
Ibandronate group (p¼0.019) [16,17]. In a small open-label pilot
study of 18 patients with severe bone pain due to metastatic bone
disease, short-term and intensive treatment with Ibandronate in-
travenously showed to have a high analgetic effect. Ibandronate 4 mg
was infused for 2 h for 4 consecutive days. Within 7 days bone pain
scores were signiﬁcantly reduced, pain reduction was sustained over
the whole study period of 6 weeks. Furthermore, improvements
were seen in patients quality of life, patient functioning and perfor-
mance status [2]. Altundag et al. observed in their phase II study of
loading-dose Ibandronate treatment in patients with painful meta-
static bone disease due to breast cancer a signiﬁcant analgetic effect
of the infused Ibandronate. 13 women with breast cancer, bone
metastases and moderate/severe pain received 6 mg Ibandronate
intravenously over 15 min over 3 consecutive days. During thefollow-up period of 14 days pain level and analgesic use decreased
signiﬁcantly. Karnofsky performance index as a marker of functional
impairment increased from day 0 (77.7) to day 14 (80.8). No renal
safety concerns or other serious adverse effects were reported [12]. In
11 Austrian breast cancer patients with severe pain, insufﬁciently
controlled by standard analgetics, an infusion of 6 mg Ibandronate i.v.
for 3 consecutive days led to a signiﬁcant decrease of pain (VASo5)
in all patients. Analgetic use was reduced within 3 days, and the
WHO performance score was improved [18]. The reduction of bone
pain under Ibandronate treatment has previously been observed in a
phase III randomized trial of patients with bone metastases and
breast cancer receiving 6 mg Ibandronte i.v every 3–4 weeks. A sig-
niﬁcant reduction in bone pain score was observed within 4 weeks
after the ﬁrst infusion with Ibandronate 6 mg compared to a placebo.
The Ibandronate-receiving patients remained on decreased pain le-
vels throughout the 2-year study period [13]. Currently, there are no
head-to head trials comparing the efﬁcacy of high intense loading-
dose Ibandronate i.v. therapy regimen for metastatic bone pain ver-
sus other bsiphosphonates [12]. Barrett-Lee et al. compared the ef-
ﬁcacy of oral ibandronic acid versus intravenous zoledronic acid in
the treatment of bone metastases from breast cancer in their open
label, non-inferiority phase III trial. 705 patients received oral iban-
dronic acid 50 mg daily, 699 patients were treated with intravenous
zoledronic acid at 4 mg every 3–4 weeks. Their results suggest that
both drugs have acceptable side-effects and are options to prevent
skeletal-related events caused by bone metastases. Pain scores
showed a reduction in both study groups from baseline at 12 weeks,
this reduction seemed to be maintained throughout the whole fol-
low-up period of 96 weeks [18]. Compared to these results our data
suggests that using a loading-dose treatment of Ibandronate in me-
tastatic bone disease is associated with a faster reduction in bone
pain compared to the standard therapeutic regimen. The intensive
loading-dose regimen was not associated with any strong adverse
effects. One patient experienced a ﬂu-like syndrome (fever, myalgia)
that lasted for 48 h. No renal or gastrointestinal side effects were
noted. Parameters as hemotology, blood chemistry, urine analyses
and renal function stayed in physiological levels for the whole follow-
up period. These results are in line with former studies, where i.v.
Ibandronate 6 mg has been shown not to be associated with at-
tenuation in renal function [19]. Opioid-resistent bone pain is difﬁ-
cult to manage, fast and relieving therapeutical options are scarce but
needed. Therefore, the loading-dose therapy with 6 mg Ibandronate
i.v. may offer a promising new therapeutic modality for patients with
severe metastatic bone pain. In the current study, we were able to
demonstrate fast and safe analgetic effects of intensive Ibandronate
therapy. The rapid improvement in patients pain level should im-
prove these patients quality of life. The positive effects of loading-
dose Ibandronate therapy seen in this study, needs further in-
vestigation in controlled clinical trials of opioid-resistent pain due to
metastatic bone disease.Ethical approval
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the in-
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